Search

Your search keyword '"Olesinska, Marzena"' showing total 47 results

Search Constraints

Start Over You searched for: Author "Olesinska, Marzena" Remove constraint Author: "Olesinska, Marzena"
47 results on '"Olesinska, Marzena"'

Search Results

2. Factors associated with quality of life in systemic sclerosis : a cross-sectional study

3. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

5. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products

6. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups

7. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)

9. 2021 DORIS definition of remission in SLE: final recommendations from an international task force

11. IL-1β, IL-10 and TNF-α polymorphisms may affect systemic lupus erythematosus risk and phenotype

12. 2021 DORIS definition of remission in SLE: final recommendations from an international task force.

13. 2021 DORIS definition of remission in SLE:Final recommendations from an international task force

15. Tocilizumab in systemic sclerosis:a randomised, double-blind, placebo-controlled, phase 3 trial

17. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

18. The Role of MECP2 and CCR5 Polymorphisms on the Development and Course of Systemic Lupus Erythematosus

24. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS).

25. 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups

26. A framework for remission in SLE:consensus findings from a large international task force on definitions of remission in SLE (DORIS)

27. Proposal for a Candidate Core Set of Fitness and Strength Tests for Patients with Childhood or Adult Idiopathic Inflammatory Myopathies

29. 03.15 Identification of novel micrornas in monocytes from rheumatoid arthritis and systemic sclerosis patients using next generation sequencing

30. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)

34. <italic>HIF-1A</italic> gene polymorphisms and its protein level in patients with rheumatoid arthritis: a case-control study.

40. Genetic Polymorphisms of Foxp3in Patients with Rheumatoid Arthritis

41. IL-10, IL-12B and IL-17 gene polymorphisms in patients with mixed connective tissue disease.

42. Health-related quality of life impairment is equal for antiphospholipid syndrome whether primary or associated with systemic lupus erythematosus.

43. Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model

44. Update of EULAR recommendations for the treatment of systemic sclerosis

45. IL-1β, IL-10 and TNF-α polymorphisms may affect systemic lupus erythematosus risk and phenotype.

46. IL-6 and TGF-β gene polymorphisms, their serum levels, as well as HLA profile, in patients with systemic lupus erythematosus.

47. 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups.

Catalog

Books, media, physical & digital resources